The CCDC120 Knockout K-562 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout population of K-562 cells, generated through CRISPR/Cas9-mediated disruption of the CCDC120 gene. This loss-of-function model eliminates CCDC120 expression across a heterogeneous cell pool, enabling the study of gene function without the bias of clonal selection. The polyclonal format reflects population-level biological responses, making it suitable for assays requiring averaged readouts.
The parental K-562 cell line is a human chronic myelogenous leukemia (CML) lymphoblast model derived from a 53-year-old female in blast crisis. These Philadelphia chromosome-positive cells express the BCR-ABL1 fusion oncogene, driving constitutive tyrosine kinase signaling, and are widely used for investigating BCR-ABL biology, erythroid differentiation, and drug responses. Their suspension growth and genetic tractability facilitate high-throughput functional genomics.
CCDC120 encodes a coiled-coil domain-containing protein that localizes to centrosomes and participates in primary cilium formation and centrosome integrity. It interacts with centriolar proteins CEP164, CEP290, and PCM1, and associates with microtubules. Within the centrosome, CCDC120 functions in complexes involving ??-tubulin and pericentrin, influencing microtubule organization and centrosome duplication. Its loss disrupts these structures, potentially impairing mitotic spindle assembly and cell cycle progression.
In the CML context, CCDC120 knockout in K-562 cells offers a means to explore links between centrosome biology and oncogenic BCR-ABL signaling. Centrosome aberrations are implicated in leukemia pathogenesis, and CCDC120 disruption may affect proliferation, genomic stability, or differentiation. This polyclonal model allows assessment of how centrosomal protein loss impacts BCR-ABL-driven pathways and drug sensitivity.
These cells are suited for western blotting, RT-qPCR, immunofluorescence (e.g., ??-tubulin staining), flow cytometry, cell viability, and proliferation assays. They can be used in drug combination studies with BCR-ABL inhibitors or in RNA-seq to profile transcriptomic changes. The polyclonal nature also aids in averaging off-target effects. For support, contact Ascent Research.
